gefitinib,tepotinib,pembrolizumab
astrazeneca,immutep,merck
['insight,(-insights)', 'immutep']
immutep announces promising initial clinical data from insight-003 at sitc 2022 - release first activity evaluation of efti as part of triple combination therapy yields promising early results with 72.7% response rate and 90.9% disease control rate i... 